6 SURPASS-4 (NCT03730662) was a 104-week study comparing the efficacy and safety of Mounjaro 5 mg (N=328), 10 mg (N=326) and 15 mg (N=337) to insulin glargine (N=998) in adults with type 2 diabetes inadequately controlled with at least one and up to three oral antihyperglycemic medications (metformin, sulfonylureas or SGLT-2 inhibitors), who have increased cardiovascular (CV) risk
Our findings thus reveal the origin of the longevity signalling in response to germline ablation, underscoring the interaction of stem cells and their niche in metazoan ageing
These include: New formulations and delivery mechanisms Lower dose, high bioavailability innovations Blood brain barrier (BBB) penetrating designs New modalities such as ADCs and fusion proteins Routine FTO checks, composition and combination filings, and route of administration strategies will be essential to maintain advantage
Woods KA, Camacho-Hubner C, Savage MO, Clark AJ
Side effects are primarily severe gastrointestinal distress but can occasionally be more serious